Changes in Hong Kong stocks | Xuanzhu Bio-B (02575) rose more than 5% to approach the first time that Xuan Yuening, an innovative drug under Qiangao, was included in the national basic medical insurance drug catalogue

The Zhitong Finance App learned that Xuanzhu Bio-B (02575) rose more than 5% in early trading, to a high of HK$71.9, close to the previous record high of HK$72. As of press release, it rose 4.42% to HK$70.8, with a turnover of HK$22.011 million.

According to the news, Xuan Yuening, an innovative drug owned by Xuanzhu Biotech, was included in the national basic medical insurance drug catalogue for the first time. The results of this medical insurance negotiation will help improve the affordability and accessibility of pirosilil tablets among patients, promote the increase in drug marketing and sales scale, and thus have a positive impact on the long-term business development of Xuanzhu Biotech.

According to public information, as a novel CDK2/4/6 inhibitor, piroxilil tablets have the advantage of strongly inhibiting tumor cell proliferation, and were approved by the China National Drug Administration for use in specific types of advanced or metastatic breast cancer patients in May 2025. Both approved indications have been included in the 2025 national basic health insurance catalogue. In addition, marketing applications for first-line treatment of pyroxil combined with aromatase inhibitors are being reviewed.